|
Title
|
|
|
|
Association between low vitamin D status, serotonin, and clinico-biobehavioral parameters in Alzheimer’s disease
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Introduction: Studies suggest a role of vitamin D in the progression and symptomatology of Alzheimer’s disease (AD), with few in vitro studies pointing to effects on serotonergic and amyloidogenic turnover. However, limited data exist in AD patients on the potential association with cognition and behavioral and psychological signs and symptoms of dementia (BPSD). In this retrospective cross-sectional study, we, therefore, explored potential correlations of serum 25-hydroxyvitamin D3 (25(OH)D3) concentrations, indicative of vitamin D status, with serum serotonin (5-hydroxytryptamine, 5-HT) levels, cognitive/BPSD scorings, and cerebrospinal fluid (CSF) biomarker levels. Methods: Frozen serum samples of 25 well-characterized AD subjects as part of a previous BPSD cohort were analyzed, of which 15 had a neuropathologically confirmed diagnosis. Serum 25(OH)D3 levels were analyzed by means of LC-MS/MS, whereas 5-HT concentrations were quantified by competitive ELISA. Results: Among AD patients, vitamin D deficiency was highly prevalent, defined as levels below 50 nmol/L. Regression analyses, adjusted for age, gender, and psychotropic medications, revealed that serum 25(OH)D3 and 5-HT levels were positively associated (p = 0.012). Furthermore, serum 25(OH)D3 concentrations correlated inversely with CSF amyloid-beta (Aβ1-42) levels (p = 0.006), and serum 5-HT levels correlated positively with aggressiveness (p = 0.001), frontal behavior (p = 0.001), depression (p = 0.004), and partly with cognitive performance (p < 0.005). Lastly, AD patients on cholinesterase inhibitors had higher serum 25(OH)D3 (p = 0.030) and lower serum 5-HT (p = 0.012) levels. Conclusions: The molecular associations between low vitamin D status, serum 5-HT, and CSF Aβ1-42 levels are highly remarkable, warranting further mechanistic and intervention studies to disclose potential involvement in the clinico-biobehavioral pathophysiology of AD. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Dementia and geriatric cognitive disorders. - Basel
| |
|
Publication
|
|
|
|
Basel
:
2023
| |
|
ISSN
|
|
|
|
1420-8008
| |
|
DOI
|
|
|
|
10.1159/000534492
| |
|
Volume/pages
|
|
|
|
52
:5-6
(2023)
, p. 318-326
| |
|
ISI
|
|
|
|
001085496300001
| |
|
Pubmed ID
|
|
|
|
37806302
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|